RU2008143232A - Новый класс ингибиторов гистондеацетилаз - Google Patents
Новый класс ингибиторов гистондеацетилаз Download PDFInfo
- Publication number
- RU2008143232A RU2008143232A RU2008143232/04A RU2008143232A RU2008143232A RU 2008143232 A RU2008143232 A RU 2008143232A RU 2008143232/04 A RU2008143232/04 A RU 2008143232/04A RU 2008143232 A RU2008143232 A RU 2008143232A RU 2008143232 A RU2008143232 A RU 2008143232A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- alkyl
- oxopropenyl
- hydrogen
- acrylamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
Abstract
1. Соединение формулы (I) !! где Q представляет собой связь, CH2, CH-NR3R4, NR5 или атом кислорода; ! Х представляет собой СН или атом азота; ! Y представляет собой связь, СН2, атом кислорода или NR6; ! Z представляет собой СН или атом азота; ! R1, R2 представляют собой, независимо, водород, галоген, (C1-C6)-алкил или (C1-C6)-галогеналкил; ! R3, R4 представляют собой, независимо, водород, (C1-C6)-алкил, фенил или бензил; ! R5 представляет собой водород, (C1-C6)-алкил, (CO)R7, SO2-(C1-C6)-алкил, фенил или бензил; ! R6 представляет собой водород, (C1-C6)-алкил или бензил; ! R7 представляет собой водород, (C1-C6)-алкил, фенил, бензил, OR8 или NR9R10; ! R8 представляет собой (C1-C6)-алкил; ! R9 представляет собой водород, (C1-C6)-алкил, фенил или бензил; !R10 представляет собой водород, (C1-C6)-алкил или бензил; ! R11, R12 представляют собой, независимо, водород или (C1-C6)-алкил; ! и его фармацевтически приемлемые соли; ! при условии, что когда Х представляет собой атом азота, Y не может представлять собой атом кислорода или NR6; ! и за исключением соединений ! (Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламида; ! (Е)-N-гидрокси-3-{4-[(Е)-3-(4-морфолин-4-илфенил)-3-оксопропенил]фенил}акриламида; ! (Е)-3-(3-фтор-4-[(Е)-3-(4-морфолин-4-илфенил)-3-оксопропенил]фенил}-N-гидроксиакриламида. ! 2. Соединение по п.1, где один или несколько из вышеуказанных (C1-C6)-алкилов представляет собой (C1-C4)-алкильную группу. ! 3. Соединение по п.1, где ! R1, R2 представляют собой, независимо, водород, фтор, хлор, (C1-C2)-алкил или CF3; ! R3, R4 представляют собой, независимо, водород, (C1-C2)-алкил, фенил или бензил; ! R5 представляет собой водород, (C1-C2)-алкил, (CO)R7, SO2-(C1-C2)-алкил, фенил или бензил; ! R6 представляет собой водород, (C1-C2)-алкил или бензил; ! R7 п�
Claims (21)
1. Соединение формулы (I)
где Q представляет собой связь, CH2, CH-NR3R4, NR5 или атом кислорода;
Х представляет собой СН или атом азота;
Y представляет собой связь, СН2, атом кислорода или NR6;
Z представляет собой СН или атом азота;
R1, R2 представляют собой, независимо, водород, галоген, (C1-C6)-алкил или (C1-C6)-галогеналкил;
R3, R4 представляют собой, независимо, водород, (C1-C6)-алкил, фенил или бензил;
R5 представляет собой водород, (C1-C6)-алкил, (CO)R7, SO2-(C1-C6)-алкил, фенил или бензил;
R6 представляет собой водород, (C1-C6)-алкил или бензил;
R7 представляет собой водород, (C1-C6)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C6)-алкил;
R9 представляет собой водород, (C1-C6)-алкил, фенил или бензил;
R10 представляет собой водород, (C1-C6)-алкил или бензил;
R11, R12 представляют собой, независимо, водород или (C1-C6)-алкил;
и его фармацевтически приемлемые соли;
при условии, что когда Х представляет собой атом азота, Y не может представлять собой атом кислорода или NR6;
и за исключением соединений
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламида;
(Е)-N-гидрокси-3-{4-[(Е)-3-(4-морфолин-4-илфенил)-3-оксопропенил]фенил}акриламида;
(Е)-3-(3-фтор-4-[(Е)-3-(4-морфолин-4-илфенил)-3-оксопропенил]фенил}-N-гидроксиакриламида.
2. Соединение по п.1, где один или несколько из вышеуказанных (C1-C6)-алкилов представляет собой (C1-C4)-алкильную группу.
3. Соединение по п.1, где
R1, R2 представляют собой, независимо, водород, фтор, хлор, (C1-C2)-алкил или CF3;
R3, R4 представляют собой, независимо, водород, (C1-C2)-алкил, фенил или бензил;
R5 представляет собой водород, (C1-C2)-алкил, (CO)R7, SO2-(C1-C2)-алкил, фенил или бензил;
R6 представляет собой водород, (C1-C2)-алкил или бензил;
R7 представляет собой водород, (C1-C2)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C2)-алкил;
R9 представляет собой водород, (C1-C2)-алкил, фенил или бензил;
R10 представляет собой водород, (C1-C2)-алкил или бензил;
R11, R12 представляют собой, независимо, водород или (C1-C2)-алкил.
4. Соединение по п.1, имеющее формулу (Ia)
где Q представляет собой СН2, CH-NR3R4 или NR5;
Х представляет собой СН или атом азота;
R1, R2 представляют собой, независимо, водород, галоген, (C1-C4)-алкил или (C1-C4)-галогеналкил;
R3, R4 представляют собой, независимо, водород или (C1-C4)-алкил;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, фенил или бензил;
R6 представляет собой водород, (C1-C6)-алкил или бензил;
R7 представляет собой водород, (C1-C6)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C4)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C4)-алкил.
5. Соединение по п.4, где
Q представляет собой CH2, CH-NR3R4 или NR5;
X представляет собой СН или атом азота;
R1, R2 представляют собой, независимо, водород, фтор, хлор или CF3;
R3, R4 представляют собой, независимо, водород или (C1-C2)-алкил;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, фенил или бензил;
R6 представляет собой водород, (C1-C6)-алкил или бензил;
R7 представляет собой водород, (C1-C4)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C2)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C2)-алкил.
6. Соединение по п.4, где
Q представляет собой NR5;
Х представляет собой атом азота;
R1, R2 представляют собой, независимо, водород, фтор, хлор или CF3;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, фенил или бензил;
R7 представляет собой водород, (С1-С4)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C2)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C2)-алкил.
7. Соединение по п.4, выбранное из группы, в которую входят
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-3-(4-{(Е)-3-[4-(4-диметиламинопиперидин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(1-метилпиперидин-4-илметил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-N-гидрокси-3-{4-[(Е)-3-оксо-3-(4-пиперазин-1-илметилфенил)пропенил]фенил}акриламид;
(Е)-3-(4-{(Е)-3-[4-(4-бензилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-((3R,5S)-3,5-диметилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-(4-ацетилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-((3R,5S)-4-ацетил-3,5-диметилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-(4-этилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[3-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[2-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}фенил)акриламид.
8. Соединение по п.1, имеющее формулу (Ib)
где Q представляет собой CH2, CH-NR3R4 или NR5;
Х представляет собой СН или атом азота;
R1, R2 представляют собой, независимо, водород, галоген, (C1-C4)-алкил или (C1-C4)-галогеналкил;
R3, R4 представляют собой, независимо, водород или (C1-C4)-алкил;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, SO2-(C1-C4)-алкил, фенил или бензил;
R7 представляет собой водород, (C1-С6)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C4)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C4)-алкил;
за исключением соединения
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламида.
9. Соединение по п.8, где в рамках указанной формулы (Ib) группа
находится в орто- или мета-положении относительно 3-оксопропенильной группы; и
Q представляет собой СН2 или NR5;
Х представляет собой СН или атом азота;
R1, R2 представляют собой, независимо, водород, фтор, хлор или CF3;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, фенил или бензил;
R7 представляет собой водород, (C1-C4)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C2)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C2)-алкил.
10. Соединение по п.8, выбранное из группы, в которую входят
(Е)-3-(4-{(Е)-3-[5-хлор-2-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидрокси акриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[2-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[3-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метиламинопиперидин-1-ил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-3-(4-{(Е)-3-[4-(4-диметиламинопиперидин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(1-метилпиперидин-4-ил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-изобутилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламид;
(Е)-3-(4-{(Е)-3-[4-(4-этилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-(4-бензилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-{4-[(Е)-3-(4-пиперазин-1-илфенил)-3-оксопропенил]фенил}акриламид;
(Е)-3-(4-{(Е)-3-[4-(4-бензоилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[4-(4-ацетилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(4-{(Е)-3-[4-(4-метансульфонилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)акриламид;
диметиламид 4-(4-{(Е)-3-[4-((Е)-2-гидроксикарбамоилвинил)фенил]акрилоил}фенил)пиперазин-1-карбоновой кислоты;
амид 4-(4-{(Е)-3-[4-((Е)-2-гидроксикарбамоилвинил)фенил]акрилоил}фенил)пиперазин-1-карбоновой кислоты;
этиловый эфир 4-(4-{(Е)-3-[4-((Е)-2-гидроксикарбамоилвинил)фенил]акрилоил}фенил)пиперазин-1-карбоновой кислоты;
(Е)-N-гидрокси-3-(4-{(Е)-3-оксо-3-[4-((3R,5S)-3,4,5-триметилпиперазин-1-ил)фенил]пропенил}фенил)акриламид;
(Е)-3-(4-{(Е)-3-[3-хлор-5-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид;
(Е)-3-(4-{(Е)-3-[2-хлор-5-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}фенил)-N-гидроксиакриламид.
11. Соединение по п.1, имеющее формулу (Ic)
где Q представляет собой СН2, CH-NR3R4, NR5 или атом кислорода;
Х представляет собой СН или атом азота;
Y представляет собой связь, СН2, атом кислорода или NR6;
R1, R2 представляют собой, независимо, водород, галоген, (C1-C4)-алкил или (C1-C4)-галогеналкил;
R3, R4 представляют собой, независимо, водород или (C1-C4)-алкил;
R5 представляет собой водород, (C1-C4)-алкил, (CO)R7, фенил или бензил;
R6 представляет собой водород или (C1-C4)-алкил;
R7 представляет собой водород, (C1-C6)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, представляет собой водород или (C1-C4)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C4)-алкил;
при условии, что когда Х представляет собой атом азота, Y не может представлять собой атом кислорода или NR6.
12. Соединение по п.11, где
Q представляет собой СН2, NR5 или атом кислорода;
Х представляет собой СН или атом азота;
Y представляет собой связь или СН2;
R1, R2 представляют собой, независимо, водород, фтор, хлор или CF3;
R5 представляет собой водород, (C1-C2)-алкил, (CO)R7, фенил или бензил;
R7 представляет собой водород, (C1-C4)-алкил, фенил, бензил, OR8 или NR9R10;
R8 представляет собой (C1-C4)-алкил;
R9, R10 представляют собой, независимо, водород или (C1-C2)-алкил;
R11, R12 представляют собой, независимо, водород или (C1-C2)-алкил.
13. Соединение по п.11, выбранное из группы, в которую входят
(Е)-N-гидрокси-3-(5-{(Е)-3-[4-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[2-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[3-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-3-(5-{(Е)-3-[4-(4-бензилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-оксо-3-[4-((3R,5S)-3,4,5-триметилпиперазин-1-ил)фенил]пропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-{5-[(Е)-3-(4-морфолин-4-илметилфенил)-3-оксопропенил]пиридин-2-ил}акриламид;
(Е)-3-(5-{(Е)-3-[4-(4-этилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)-N-гидроксиакриламид;
(Е)-3-(5-{(Е)-3-[4-(4-ацетилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-оксо-3-[3-((3R,5S)-3,4,5-триметилпиперазин-1-ил)фенил]пропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[4-(1-метилпиперидин-4-илметил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-{5-[(Е)-3-оксо-3-(4-пиперазин-1-илфенил)пропенил]пиридин-2-ил}акриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[2-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-N-гидрокси-3-{5-[(Е)-3-оксо-3-(4-пиперазин-1-илметилфенил)пропенил]пиридин-2-ил}акриламид;
(Е)-3-(5-{(Е)-3-[4-(4-ацетилпиперазин-1-илметил)фенил]-3-оксопропенил}пиридин-2-ил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[4-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид;
(Е)-3-(5-{(Е)-3-[3-хлор-5-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил}пиридин-2-ил)-N-гидроксиакриламид;
(Е)-N-гидрокси-3-(5-{(Е)-3-[3-(4-метилпиперазин-1-илметил)фенил]-3-оксопропенил}пиридин-2-ил)акриламид.
15. Способ по п.14, где соединение формулы (II) получают из соединения формулы (V) или из соединения формулы (XI)
где X, Y, R1, R2, R11, R12 и Z имеют значения, указанные для формулы (I), и W1 представляет собой NH, и W2 представляет собой СО, обработанных реагентами, способными превращать группу W1 или W2 в Q, имеющий значения, указанные для формулы (I).
17. Соединение формулы (I), (Ia), (Ib), (Ic) по пп.1-13 для применения в терапии.
18. Фармацевтическая композиция, включающая одно или несколько соединений формулы (I), (Ia), (Ib), (Ic) по пп.1-13 в сочетании с фармацевтически приемлемыми эксципиентами.
19. Композиция по п.18 в форме таблетки, капсулы, пилюли, перорального препарата, порошка, гранулированного препарата, раствора для инъекции или инфузии, суппозитория, водной или масляной суспензии, раствора, эмульсии, сиропа, эликсира, крема, мази, пасты, геля, раствора, масла или лосьона, мембраны или лечебного пэтча.
20. Применение одного или нескольких соединений формулы (I), (Ia), (Ib), (Ic) по пп.1-13 при получении лечебного средства для предупреждения и/или лечения заболеваний, связанных с разрегулированием гистондеацетилазной активности.
21. Применение по п.20, где указанным заболеванием является рак.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2006A000621 | 2006-03-31 | ||
IT000621A ITMI20060621A1 (it) | 2006-03-31 | 2006-03-31 | Nuova classe di inibitori delle istone deacetilasi |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008143232A true RU2008143232A (ru) | 2010-05-10 |
RU2420522C2 RU2420522C2 (ru) | 2011-06-10 |
Family
ID=38279235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008143232/04A RU2420522C2 (ru) | 2006-03-31 | 2007-03-30 | Новый класс ингибиторов гистондеацетилаз |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100113438A1 (ru) |
EP (1) | EP2049508B1 (ru) |
JP (1) | JP5167241B2 (ru) |
KR (1) | KR20090018883A (ru) |
CN (1) | CN101448802B (ru) |
AT (1) | ATE470663T1 (ru) |
AU (1) | AU2007233732B2 (ru) |
BR (1) | BRPI0709283A2 (ru) |
CA (1) | CA2647445C (ru) |
DE (1) | DE602007007092D1 (ru) |
ES (1) | ES2347183T3 (ru) |
HK (1) | HK1126755A1 (ru) |
IL (1) | IL194422A0 (ru) |
IT (1) | ITMI20060621A1 (ru) |
MX (1) | MX2008012466A (ru) |
NZ (1) | NZ572147A (ru) |
RU (1) | RU2420522C2 (ru) |
WO (1) | WO2007113249A2 (ru) |
ZA (1) | ZA200809025B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
EP2311840A1 (en) * | 2009-10-13 | 2011-04-20 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
US8980877B2 (en) | 2008-04-15 | 2015-03-17 | Dac S.R.L. | Spirocyclic derivatives as histone deacetylase inhibitors |
EP2133334A1 (en) * | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
PT2658844T (pt) | 2010-12-28 | 2017-01-24 | Sanofi Sa | Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb) |
GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
CN103102332B (zh) * | 2013-01-17 | 2015-05-27 | 浙江大学 | 含哌嗪环的查尔酮类化合物及其制备和应用 |
CN103102331B (zh) * | 2013-01-17 | 2015-05-27 | 浙江大学 | 含哌嗪环的查尔酮类化合物的药物用途 |
CN108164476B (zh) * | 2016-12-08 | 2021-01-26 | 沈阳化工研究院有限公司 | 间苯二腈类化合物、其应用以及包含该化合物的药物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013264A1 (fr) * | 1993-11-08 | 1995-05-18 | Terumo Kabushiki Kaisha | Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive |
JPH09268125A (ja) * | 1996-04-02 | 1997-10-14 | Terumo Corp | 腎炎治療薬 |
FR2796951A1 (fr) * | 1999-07-26 | 2001-02-02 | Centre Nat Rech Scient | Complexes de phosphine/palladium, utiles comme catalyseurs notamment pour l'arylation d'olefines |
CA2391952C (en) * | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
AR046605A1 (es) * | 2003-10-27 | 2005-12-14 | S Bio Pte Ltd | Hidroxamatos unidos a biarilo; preparacion y aplicaciones farmaceuticas |
TW200530166A (en) * | 2003-10-27 | 2005-09-16 | S Bio Pte Ltd | Acylurea connected and sulfonylurea connected hydroxamates |
ITMI20041869A1 (it) * | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
-
2006
- 2006-03-31 IT IT000621A patent/ITMI20060621A1/it unknown
-
2007
- 2007-03-30 ES ES07727569T patent/ES2347183T3/es active Active
- 2007-03-30 US US12/295,498 patent/US20100113438A1/en not_active Abandoned
- 2007-03-30 CN CN200780018172XA patent/CN101448802B/zh not_active Expired - Fee Related
- 2007-03-30 NZ NZ572147A patent/NZ572147A/en not_active IP Right Cessation
- 2007-03-30 KR KR1020087025469A patent/KR20090018883A/ko not_active Application Discontinuation
- 2007-03-30 CA CA2647445A patent/CA2647445C/en not_active Expired - Fee Related
- 2007-03-30 DE DE602007007092T patent/DE602007007092D1/de active Active
- 2007-03-30 RU RU2008143232/04A patent/RU2420522C2/ru not_active IP Right Cessation
- 2007-03-30 AT AT07727569T patent/ATE470663T1/de not_active IP Right Cessation
- 2007-03-30 BR BRPI0709283-0A patent/BRPI0709283A2/pt not_active IP Right Cessation
- 2007-03-30 WO PCT/EP2007/053097 patent/WO2007113249A2/en active Application Filing
- 2007-03-30 AU AU2007233732A patent/AU2007233732B2/en not_active Ceased
- 2007-03-30 MX MX2008012466A patent/MX2008012466A/es active IP Right Grant
- 2007-03-30 EP EP07727569A patent/EP2049508B1/en not_active Not-in-force
- 2007-03-30 JP JP2009502111A patent/JP5167241B2/ja not_active Expired - Fee Related
-
2008
- 2008-09-28 IL IL194422A patent/IL194422A0/en unknown
- 2008-10-21 ZA ZA200809025A patent/ZA200809025B/xx unknown
-
2009
- 2009-05-15 HK HK09104436.5A patent/HK1126755A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2007233732A1 (en) | 2007-10-11 |
ITMI20060621A1 (it) | 2007-10-01 |
DE602007007092D1 (de) | 2010-07-22 |
WO2007113249A2 (en) | 2007-10-11 |
CA2647445C (en) | 2014-08-19 |
RU2420522C2 (ru) | 2011-06-10 |
WO2007113249A3 (en) | 2007-11-29 |
CA2647445A1 (en) | 2007-10-11 |
MX2008012466A (es) | 2008-10-10 |
AU2007233732B2 (en) | 2012-02-02 |
IL194422A0 (en) | 2009-08-03 |
ES2347183T3 (es) | 2010-10-26 |
KR20090018883A (ko) | 2009-02-24 |
EP2049508A2 (en) | 2009-04-22 |
NZ572147A (en) | 2010-11-26 |
CN101448802A (zh) | 2009-06-03 |
ATE470663T1 (de) | 2010-06-15 |
US20100113438A1 (en) | 2010-05-06 |
JP2009531393A (ja) | 2009-09-03 |
JP5167241B2 (ja) | 2013-03-21 |
CN101448802B (zh) | 2012-11-07 |
BRPI0709283A2 (pt) | 2011-07-05 |
HK1126755A1 (en) | 2009-09-11 |
ZA200809025B (en) | 2009-07-29 |
EP2049508B1 (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
JP4792186B2 (ja) | スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用 | |
JP2005513123A5 (ru) | ||
CA2396158A1 (en) | Dipeptide nitrile cathepsin k inhibitors | |
JP2007519619A5 (ru) | ||
RU2012129737A (ru) | Замещенные бензамидные производные | |
RU2007107189A (ru) | Производные арилпиридина | |
JP2006504656A5 (ru) | ||
JP2008517926A5 (ru) | ||
JP2007519754A5 (ru) | ||
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
JP2005508923A5 (ru) | ||
RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
RU2008129723A (ru) | Ингибиторы ccr9 активности | |
JP2006510609A5 (ru) | ||
RU2008129641A (ru) | Ингибиторы ccr9 активности | |
CA2608837A1 (en) | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors | |
EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
RU2008129623A (ru) | Ингибиторы ccr9 активности | |
JP2009528997A5 (ru) | ||
RU2007131423A (ru) | Новые производные 3-фенилпропионовой кислоты | |
JP2006512321A5 (ru) | ||
ES2715394T3 (es) | Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130331 |